Document is current
Any future updates will be listed below
-
Authors
Appleton, Ellen
Khosousi, Shervin
Ta, Michael
Nalls, Michael
Singleton, Andrew B.
Sturchio, Andrea
Markaki, Ioanna
Paslawski, Wojciech
Iwaki, Hirotaka
Svenningsson, Per http://orcid.org/0000-0001-6727-3802
-
Funding
Funding for this research was provided by:
Knut och Alice Wallenbergs Stiftelse (2022)
NHLBI Division of Intramural Research (NIA)
Science for Life Laboratory (2022)
Kommunfullmäktige, Stockholms Stad (2019)
- License Information
-
More Information
Article History
Received: 17 January 2024
Accepted: 9 May 2024
First Online: 11 June 2024
Declarations
:
: All study individuals from the Stockholm-based cohort gave written consent to the storage of their samples for future use in studies; and the study has been approved by the Swedish Ethical Review Authority (dnr 2020–03684). The PD patients included were additionally part of the Stockholm BioPark cohort (dnr 2019–04967) and had been clinically assessed. The PPMI study was approved by the Institutional Review Boards of each PPMI site. Informed written consent was obtained from all subjects at each site.
: Not applicable.
: H.I. and M.A.N.’s participation in this project was part of a competitive contract awarded to Data Tecnica LLC by the National Institutes of Health to support open science research. M.A.N. also currently serves on the scientific advisory board at Clover Therapeutics and is an advisor and scientific founder at Neuron23 Inc. A.S cofounded REGAIN Therapeutics and is co-inventor of the patent “Compositions and methods for treatment and/or prophylaxis of proteinopathies.” All other authors report no conflicts of interest.
